Skull metastasis of thyroid papillary carcinoma

Miyawaki, Satoru; Yamazaki, Ryuichi; Harada, Takehiko; Takanashi, Shigehiko; Nagashima, Tadashi; Nakaguchi, Hiroshi; Okazaki, Ryo; Yamazaki, Keiji; Ishida, Yasuo; Matsuno, Akira

doi:10.1016/j.jocn.2006.01.032

Cited by 11 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lung is the most common metastatic site of thyroid carcinoma, followed by the bone [11, 21, 45, 47]. Skull metastasis of thyroid carcinoma is rare, with a small number of reported cases [2–4, 6–8, 12, 19–24, 26–28, 30, 32–35, 38–40, 42, 44, 45, 49–51, 53, 54, 56, 57, 60, 63–65, 68–70, 73, 77, 78]. The largest series of skull metastasis from thyroid carcinoma reported a frequency of only 2.5% among 473 patients [45].…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological and Molecular Histochemical Review of Skull Base Metastasis from Differentiated Thyroid Carcinoma

Matsuno

Murakami

Hoya

et al. 2013

Acta Histochem. Cytochem

Self Cite

View full text Add to dashboard Cite

Skull base metastasis from differentiated thyroid carcinoma including follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma (PTC) is a rare clinical entity. Eighteen FTC cases and 10 PTC cases showing skull base metastasis have been reported. The most common symptom of skull base metastasis from FTC and PTC is cranial nerve dysfunction. Bone destruction and local invasion to the surrounding soft tissues are common on radiological imaging. Skull base metastases can be the initial clinical presentation of FTC and PTC in the presence of silent primary sites. The possibility of skull base metastasis from FTC and PTC should be considered in patients with the clinical symptoms of cranial nerve dysfunction and radiological findings of bone destruction. A variety of genetic alterations in thyroid tumors have been identified to have a fundamental role in their tumorigenesis. Molecular histochemical studies are useful for elucidating the histopathological features of thyroid carcinoma. Recent molecular findings may provide novel molecular-based treatment strategies for thyroid carcinoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinicopathological and Molecular Histochemical Review of Skull Base Metastasis from Differentiated Thyroid Carcinoma

Matsuno

Murakami

Hoya

et al. 2013

Acta Histochem. Cytochem

Self Cite

View full text Add to dashboard Cite

show abstract

“…The lung is the most common metastatic site for thyroid carcinoma followed by the bone, 7,10,26,27) but skull metastasis of thyroid carcinoma is rare, with few reported cases. [1][2][3][4][5][6][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23]25,26,[28][29][30][31][32][33][34][35][36][37][38]40,41,44,45) The largest series of skull metastasis from thyroid carcinoma reported a frequency of only 2.5% among 473 patients. 26) Moreover, skull base metastasis from differentiated thyroid carcinoma is even rarer, with only 23 reported cases, including 17 cases of skull base metastasis from FTC that involved the clivus, cavernous sinus, sella turcica, petrous apex, and petrous ridge.…”

Section: Introductionmentioning

confidence: 99%

Skull Base Metastasis From Follicular Thyroid Carcinoma -Two Case Reports-

Matsuno

Katakami

Okazaki

et al. 2010

Neurol. Med. Chir.(Tokyo)

Self Cite

View full text Add to dashboard Cite

A 58-year-old woman and a 71-year-old woman presented with extremely rare skull base metastases from follicular thyroid carcinoma (FTC). Surgical removal and external radiotherapy were performed followed by iodine-131 ( 131 I) brachytherapy and thyroid hormone administration. The metastatic tumors in the skull base were well controlled. Treatment for skull base metastasis from FTC includes surgical debulking of the metastatic lesion, as well as complete resection of the thyroid gland, followed by internal irradiation with 131 I, external irradiation, and administration of thyroid hormone to prevent tumor growth by suppression of endogenous thyroid-stimulating hormone. Skull base metastases may be the initial clinical presentation of FTC, with silent primary sites. The possibility of skull base metastasis from FTC should be considered in patients with clinical symptoms of cranial nerve dysfunction and radiological findings of bone destruction.

show abstract

“…The youngest patient was a 55-year-old Japanese woman with parietal skull metastasis, 2 years after diagnosis of PTC. 8 Another 70-year-old Japanese woman had cervical lymph node metastasis and parietal skull metastasis 7 and 12 years, respectively, after of lobectomy for PTC stage T4N1M0. 9 A 74-year-old woman with history of neurofibromatosis type 1 and pheochromocytoma had a skull metastasis from PTC after 23 years of curative surgery for PTC.…”

Section: Discussionmentioning

confidence: 99%

“…6,7 Skull metastasis from papillary thyroid carcinoma is extremely rare and usually presents as a soft painless slow-growing scalp mass. 8 The metastatic lesion is usually hypervascular, and osteolytic with involvement of the subcutaneous tissue on radiological examination. 6 It rarely causes increased intracranial pressure or brain compression, but occasionally an intracranial extension causes severe neurological symptoms.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Papillary thyroid carcinoma with metastasis to the frontal skull

Feng

Rhatigan

Shuja

et al. 2009

Diagnostic Cytopathology

View full text Add to dashboard Cite

Papillary thyroid carcinoma with metastasis to the frontal skull is extremely rare. We report a case of unsuspected papillary thyroid carcinoma with frontal skull metastasis. The patient was a 62-year-old African American woman with presentation of a 4-cm firm, painless, immobile, ill-defined mass at the right forehead. Ultrasound and computer tonography detected a hypervascular and osteolytic tumor involving the skull and overlying skin. Fine-needle aspiration was performed followed by surgical biopsy. Cytologic examination revealed the presence of hypercellular and bloody material. The neoplasm showed glandular features and was composed of clusters of round to oval cells with pinkish squamoid cytoplasm, oval nuclei and inconspicuous nucleoli on smears and sections of cell block. With immunocytochemical stain, the neoplastic cells were positive for pancytokeratin and vimentin and focally positive for EMA, while they were negative for S100, HMB45, Melan-A, CD34, GFAP, CD10, LCA, RCC and CD138. The diagnosis was a metastatic carcinoma. Clinical follow up with surgical biopsy was recommended. Surgical biopsy demonstrated histological and cytological features of papillary thyroid carcinoma including prominent papillae, nuclear overlapping, grooves, and intranuclear pseudoinclusions. Thus, a diagnosis of metastatic papillary thyroid carcinoma was rendered. Though skull metastasis of thyroid carcinoma is rare, it should be considered in the differential diagnosis when a skull mass lesion is encountered.

show abstract

Skull metastasis of thyroid papillary carcinoma

Cited by 11 publications

References 13 publications

Clinicopathological and Molecular Histochemical Review of Skull Base Metastasis from Differentiated Thyroid Carcinoma

Clinicopathological and Molecular Histochemical Review of Skull Base Metastasis from Differentiated Thyroid Carcinoma

Skull Base Metastasis From Follicular Thyroid Carcinoma -Two Case Reports-

Papillary thyroid carcinoma with metastasis to the frontal skull

Contact Info

Product

Resources

About